The lead KAT-CIP, which we named TCIP3, activated BCL6-target gene expression and inhibited proliferation in DLBCL cells at sub-nanomolar IC50s without exhibiting toxicity in non-transformed tonsillar lymphocytes or fibroblasts. The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.